Winald R. Gerritsen

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Joaquim Bellmunt, Ronald de Wit, David J. Vaughn et al. · New England Journal of Medicine · 2017 · 3.3K citations · Full text

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer

Tomasz M. Beer, Eugene D. Kwon, Charles G. Drake et al. · Journal of Clinical Oncology · 2016 · 742 citations · Full text

Pharmacotherapy, Immunotherapeutics, Immunotherapy +16

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Yves Fradet, Joaquim Bellmunt, David J. Vaughn et al. · Annals of Oncology · 2019 · 473 citations · Full text

Blood platelets contain tumor-derived RNA biomarkers

R. Jonas A. Nilsson, Leonora Balaj, Esther Hulleman et al. · Blood · 2011 · 383 citations · Full text